{
    "items": [
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/moa-and-nufarm-announce-next-phase-for-their-novel-mode-of-action-herbicide\" title=\"Moa and Nufarm announce next phase for their novel mode of action herbicide\" class=\"state-published\">Moa and Nufarm announce next phase for their novel mode of action herbicide</a>\n            </h4>\n            \n            \n                \n\n    \n    \n        <ul class=\"list-unstyled list-inline categories-list\">\n\t        \n\t        \t\t<li>\n\t\t            <a href=\"https://www.bioescalator.ox.ac.uk/search?category=alumni-news\" title=\"Alumni news\">\n\t\t                <span class=\"label label-primary\">Alumni news</span>\n\t\t            </a>\n\t\t        </li>\n\t        \n\t   \t</ul>\n\n    \n\n\n            \n\n            \n                <p class=\"details\" itemprop=\"datePublished\">17 September 2025</p>\n            \n                            \n            \n                <p data-truncate=\"yes\" data-truncate-lines=\"2\">First phase completed a year earlier than typical industry timelines</p>\n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/alchemab-therapeutics-initiates-phase-1-clinical-trial-of-atlx-1282-and-announces-series-a-financing-extension\" title=\"Alchemab Therapeutics initiates Phase 1 clinical trial of ATLX-1282 and announces Series A financing extension\" class=\"state-published\">Alchemab Therapeutics initiates Phase 1 clinical trial of ATLX-1282 and announces Series A financing extension</a>\n            </h4>\n            \n            \n                \n\n    \n    \n        <ul class=\"list-unstyled list-inline categories-list\">\n\t        \n\t        \t\t<li>\n\t\t            <a href=\"https://www.bioescalator.ox.ac.uk/search?category=alumni-news\" title=\"Alumni news\">\n\t\t                <span class=\"label label-primary\">Alumni news</span>\n\t\t            </a>\n\t\t        </li>\n\t        \n\t   \t</ul>\n\n    \n\n\n            \n\n            \n                <p class=\"details\" itemprop=\"datePublished\">8 September 2025</p>\n            \n                            \n            \n                <p data-truncate=\"yes\" data-truncate-lines=\"2\">Follows successful completion of pre-clinical activities by Alchemab as part of an earlier licensing deal with Eli Lilly and Company for ATLX-1282. Financing included participation from Eli Lilly and Company and Ono Venture Investment alongside significant support from world-class existing investors.</p>\n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/omass-therapeutics-enters-into-exclusive-collaboration-and-license-agreement-with-genentech-to-develop-and-commercialise-therapies-for-inflammatory-bowel-disease\" title=\"OMass Therapeutics enters into exclusive collaboration and license agreement with Genentech to develop and commercialise therapies for inflammatory bowel disease\" class=\"state-published\">OMass Therapeutics enters into exclusive collaboration and license agreement with Genentech to develop and commercialise therapies for inflammatory bowel disease</a>\n            </h4>\n            \n            \n                \n\n    \n    \n        <ul class=\"list-unstyled list-inline categories-list\">\n\t        \n\t        \t\t<li>\n\t\t            <a href=\"https://www.bioescalator.ox.ac.uk/search?category=alumni-news\" title=\"Alumni news\">\n\t\t                <span class=\"label label-primary\">Alumni news</span>\n\t\t            </a>\n\t\t        </li>\n\t        \n\t   \t</ul>\n\n    \n\n\n            \n\n            \n                <p class=\"details\" itemprop=\"datePublished\">1 September 2025</p>\n            \n                            \n            \n                <p data-truncate=\"yes\" data-truncate-lines=\"2\">Collaboration leverages OMass\u2019 OdyssionTM platform for the continued development of oral small molecules against a first-in-class target in inflammatory bowel disease. OMass to receive $20M upfront payment, with potential for more than $400M in additional milestone payments, as well as tiered royalties on net sales.</p>\n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/moa-develops-groundbreaking-category-of-crop-protection-signs-partnership-deal-with-gowan\" title=\"Moa develops groundbreaking category of crop protection; signs partnership deal with Gowan\" class=\"state-published\">Moa develops groundbreaking category of crop protection; signs partnership deal with Gowan</a>\n            </h4>\n            \n            \n                \n\n    \n    \n        <ul class=\"list-unstyled list-inline categories-list\">\n\t        \n\t        \t\t<li>\n\t\t            <a href=\"https://www.bioescalator.ox.ac.uk/search?category=alumni-news\" title=\"Alumni news\">\n\t\t                <span class=\"label label-primary\">Alumni news</span>\n\t\t            </a>\n\t\t        </li>\n\t        \n\t   \t</ul>\n\n    \n\n\n            \n\n            \n                <p class=\"details\" itemprop=\"datePublished\">25 August 2025</p>\n            \n                            \n            \n                <p data-truncate=\"yes\" data-truncate-lines=\"2\">OXFORD UK: Moa Technology today announces its discovery of chemistries which could become an entirely new category of products to help farmers protect their harvests more safely, sustainably and effectively.</p>\n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/theolytics-featured-in-innovate-uk-case-study-harnessing-the-power-of-cancer-killing-viruses\" title=\"Theolytics featured in Innovate UK Case Study: Harnessing the power of cancer-killing viruses\" class=\"state-published\">Theolytics featured in Innovate UK Case Study: Harnessing the power of cancer-killing viruses</a>\n            </h4>\n            \n            \n                \n\n    \n    \n        <ul class=\"list-unstyled list-inline categories-list\">\n\t        \n\t        \t\t<li>\n\t\t            <a href=\"https://www.bioescalator.ox.ac.uk/search?category=alumni-news\" title=\"Alumni news\">\n\t\t                <span class=\"label label-primary\">Alumni news</span>\n\t\t            </a>\n\t\t        </li>\n\t        \n\t   \t</ul>\n\n    \n\n\n            \n\n            \n                <p class=\"details\" itemprop=\"datePublished\">6 August 2025</p>\n            \n                            \n            \n                <p data-truncate=\"yes\" data-truncate-lines=\"2\">Theolytics has created an extensive proprietary library of oncolytic viruses (viruses that kill cancer cells) to harness their potential to safely target and destroy tumour cells while leaving healthy cells intact.</p>\n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/omass-therapeutics-appoints-carol-a-schafer-as-non-executive-director-and-chair-of-the-audit-committee\" title=\"OMass Therapeutics appoints Carol A. Schafer as Non-Executive Director and Chair of the Audit Committee\" class=\"state-published\">OMass Therapeutics appoints Carol A. Schafer as Non-Executive Director and Chair of the Audit Committee</a>\n            </h4>\n            \n            \n                \n\n    \n    \n        <ul class=\"list-unstyled list-inline categories-list\">\n\t        \n\t        \t\t<li>\n\t\t            <a href=\"https://www.bioescalator.ox.ac.uk/search?category=alumni-news\" title=\"Alumni news\">\n\t\t                <span class=\"label label-primary\">Alumni news</span>\n\t\t            </a>\n\t\t        </li>\n\t        \n\t   \t</ul>\n\n    \n\n\n            \n\n            \n                <p class=\"details\" itemprop=\"datePublished\">5 August 2025</p>\n            \n                            \n            \n                <p data-truncate=\"yes\" data-truncate-lines=\"2\">OMass Therapeutics (\u2018OMass\u2019 or \u2018the Company\u2019), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces the appointment of Carol A. Schafer as non-executive Director and Chair of the Audit Committee.</p>\n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/biotech-start-up-ochre-bio-relocates-to-alexandria-center-r-for-life-science-2013-new-york-city\" title=\"Biotech start-up Ochre Bio relocates to Alexandria Center\u00ae for Life Science \u2013 New York City\" class=\"state-published\">Biotech start-up Ochre Bio relocates to Alexandria Center\u00ae for Life Science \u2013 New York City</a>\n            </h4>\n            \n            \n                \n\n    \n    \n        <ul class=\"list-unstyled list-inline categories-list\">\n\t        \n\t        \t\t<li>\n\t\t            <a href=\"https://www.bioescalator.ox.ac.uk/search?category=alumni-news\" title=\"Alumni news\">\n\t\t                <span class=\"label label-primary\">Alumni news</span>\n\t\t            </a>\n\t\t        </li>\n\t        \n\t   \t</ul>\n\n    \n\n\n            \n\n            \n                <p class=\"details\" itemprop=\"datePublished\">20 July 2025</p>\n            \n                            \n            \n                <p data-truncate=\"yes\" data-truncate-lines=\"2\">JLL announced today that it has completed a sublease for growing U.K.-based biotech company Ochre Bio at 430 East 29th St. within the Alexandria Center\u00ae for Life Science \u2013 New York City.</p>\n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/omass-therapeutics-presents-positive-preclinical-data-for-its-best-in-class-mc2-program-at-endo-2025\" title=\"OMass Therapeutics presents positive preclinical data for its Best-in-class MC2 program at ENDO 2025\" class=\"state-published\">OMass Therapeutics presents positive preclinical data for its Best-in-class MC2 program at ENDO 2025</a>\n            </h4>\n            \n            \n                \n\n    \n    \n        <ul class=\"list-unstyled list-inline categories-list\">\n\t        \n\t        \t\t<li>\n\t\t            <a href=\"https://www.bioescalator.ox.ac.uk/search?category=alumni-news\" title=\"Alumni news\">\n\t\t                <span class=\"label label-primary\">Alumni news</span>\n\t\t            </a>\n\t\t        </li>\n\t        \n\t   \t</ul>\n\n    \n\n\n            \n\n            \n                <p class=\"details\" itemprop=\"datePublished\">13 July 2025</p>\n            \n                            \n            \n                <p data-truncate=\"yes\" data-truncate-lines=\"2\">OMass Therapeutics (\u2018OMass\u2019 or \u2018the Company\u2019), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces positive preclinical data for OMS1620, its lead program targeting the melanocortin-2 (MC2) receptor, at ENDO 2025, the Annual Endocrine Society Meeting, taking place in San Francisco from 12-15 July.</p>\n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/dr-quin-wills-appointed-as-ochre-bio-ceo\" title=\"Dr Quin Wills appointed as Ochre Bio CEO\" class=\"state-published\">Dr Quin Wills appointed as Ochre Bio CEO</a>\n            </h4>\n            \n            \n                \n\n    \n    \n        <ul class=\"list-unstyled list-inline categories-list\">\n\t        \n\t        \t\t<li>\n\t\t            <a href=\"https://www.bioescalator.ox.ac.uk/search?category=alumni-news\" title=\"Alumni news\">\n\t\t                <span class=\"label label-primary\">Alumni news</span>\n\t\t            </a>\n\t\t        </li>\n\t        \n\t   \t</ul>\n\n    \n\n\n            \n\n            \n                <p class=\"details\" itemprop=\"datePublished\">29 June 2025</p>\n            \n                            \n            \n                <p data-truncate=\"yes\" data-truncate-lines=\"2\">Oxford-based Ochre Bio, a biotechnology company developing RNA therapeutics for chronic liver disease, has appointed Dr Quin Wills as CEO.</p>\n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/ochre-bio-appoints-ex-eli-lilly-and-astrazeneca-vp-as-non-executive-director\" title=\"Ochre Bio appoints ex-Eli Lilly and AstraZeneca VP as Non-Executive Director\" class=\"state-published\">Ochre Bio appoints ex-Eli Lilly and AstraZeneca VP as Non-Executive Director</a>\n            </h4>\n            \n            \n                \n\n    \n    \n        <ul class=\"list-unstyled list-inline categories-list\">\n\t        \n\t        \t\t<li>\n\t\t            <a href=\"https://www.bioescalator.ox.ac.uk/search?category=alumni-news\" title=\"Alumni news\">\n\t\t                <span class=\"label label-primary\">Alumni news</span>\n\t\t            </a>\n\t\t        </li>\n\t        \n\t   \t</ul>\n\n    \n\n\n            \n\n            \n                <p class=\"details\" itemprop=\"datePublished\">28 May 2025</p>\n            \n                            \n            \n                <p data-truncate=\"yes\" data-truncate-lines=\"2\">The appointment and ongoing science team expansion will help the company advance late-stage liver disease therapeutics.</p>\n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/pepgen-to-focus-on-development-of-promising-dm1-program-following-10-mg-kg-pgn-edo51-update\" title=\"PepGen to focus on development of promising DM1 program following 10 mg/kg PGN-EDO51 update\" class=\"state-published\">PepGen to focus on development of promising DM1 program following 10 mg/kg PGN-EDO51 update</a>\n            </h4>\n            \n            \n                \n\n    \n    \n        <ul class=\"list-unstyled list-inline categories-list\">\n\t        \n\t        \t\t<li>\n\t\t            <a href=\"https://www.bioescalator.ox.ac.uk/search?category=alumni-news\" title=\"Alumni news\">\n\t\t                <span class=\"label label-primary\">Alumni news</span>\n\t\t            </a>\n\t\t        </li>\n\t        \n\t   \t</ul>\n\n    \n\n\n            \n\n            \n                <p class=\"details\" itemprop=\"datePublished\">27 May 2025</p>\n            \n                            \n            \n                <p data-truncate=\"yes\" data-truncate-lines=\"2\">PGN-EDO51 did not achieve target dystrophin levels in CONNECT1-EDO51 trial; Company to discontinue development of DMD programs. PGN-EDO51 at 10 mg/kg was generally well tolerated; all treatment-related adverse events were mild. DM1 program on track to read out FREEDOM-DM1 15 mg/kg cohort in second half of 2025 and FREEDOM2-DM1 5 mg/kg cohort in Q1 2026.</p>\n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/nucleome-therapeutics-appoints-bhavna-hunjan-as-chief-business-officer\" title=\"Nucleome Therapeutics appoints Bhavna Hunjan as Chief Business Officer\" class=\"state-published\">Nucleome Therapeutics appoints Bhavna Hunjan as Chief Business Officer</a>\n            </h4>\n            \n            \n                \n\n    \n    \n        <ul class=\"list-unstyled list-inline categories-list\">\n\t        \n\t        \t\t<li>\n\t\t            <a href=\"https://www.bioescalator.ox.ac.uk/search?category=alumni-news\" title=\"Alumni news\">\n\t\t                <span class=\"label label-primary\">Alumni news</span>\n\t\t            </a>\n\t\t        </li>\n\t        \n\t   \t</ul>\n\n    \n\n\n            \n\n            \n                <p class=\"details\" itemprop=\"datePublished\">26 May 2025</p>\n            \n                            \n            \n                <p data-truncate=\"yes\" data-truncate-lines=\"2\">Nucleome Therapeutics (\u2018Nucleome\u2019 or \u2018the Company\u2019), a biotechnology\r\ncompany harnessing the power of non-coding human genetics to discover first-in-class antibody\r\ntreatments for inflammatory diseases, announces it has appointed Bhavna Hunjan as Chief Business\r\nOfficer with immediate effect.</p>\n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/pepgen-appoints-kasra-kasraian-phd-as-chief-technology-officer\" title=\"PepGen appoints Kasra Kasraian, PhD, as Chief Technology Officer\" class=\"state-published\">PepGen appoints Kasra Kasraian, PhD, as Chief Technology Officer</a>\n            </h4>\n            \n            \n                \n\n    \n    \n        <ul class=\"list-unstyled list-inline categories-list\">\n\t        \n\t        \t\t<li>\n\t\t            <a href=\"https://www.bioescalator.ox.ac.uk/search?category=alumni-news\" title=\"Alumni news\">\n\t\t                <span class=\"label label-primary\">Alumni news</span>\n\t\t            </a>\n\t\t        </li>\n\t        \n\t   \t</ul>\n\n    \n\n\n            \n\n            \n                <p class=\"details\" itemprop=\"datePublished\">19 May 2025</p>\n            \n                            \n            \n                <p data-truncate=\"yes\" data-truncate-lines=\"2\">PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the appointment of Kasra Kasraian, PhD, as Chief Technology Officer (CTO). Dr. Kasraian brings over 25 years of experience in product and process development, CMC strategy, and technical operations, spanning small and large molecules, as well as cell and gene therapies.</p>\n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/alchemab-therapeutics-signs-landmark-415m-licensing-agreement-for-atlx-1282-with-eli-lilly-and-company\" title=\"Alchemab Therapeutics signs landmark $415m licensing agreement for ATLX-1282 with Eli Lilly and Company\" class=\"state-published\">Alchemab Therapeutics signs landmark $415m licensing agreement for ATLX-1282 with Eli Lilly and Company</a>\n            </h4>\n            \n            \n                \n\n    \n    \n        <ul class=\"list-unstyled list-inline categories-list\">\n\t        \n\t        \t\t<li>\n\t\t            <a href=\"https://www.bioescalator.ox.ac.uk/search?category=alumni-news\" title=\"Alumni news\">\n\t\t                <span class=\"label label-primary\">Alumni news</span>\n\t\t            </a>\n\t\t        </li>\n\t        \n\t   \t</ul>\n\n    \n\n\n            \n\n            \n                <p class=\"details\" itemprop=\"datePublished\">5 May 2025</p>\n            \n                            \n            \n                <p data-truncate=\"yes\" data-truncate-lines=\"2\">Alchemab Therapeutics (Alchemab), the next generation biopharmaceutical company which uses the power of human immune evolution to identify and develop naturally occurring therapeutic antibodies from resilient individuals, today announces that it has entered into a licensing agreement with Eli Lilly and Company (Lilly) for ATLX-1282, Alchemab\u2019s first-in-class IND-ready programme for amyotrophic lateral sclerosis (ALS) and other neurodegenerative conditions.</p>\n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/enara-bio-strengthens-senior-leadership-with-key-executive-and-board-appointments-alongside-acceleration-of-multiple-t-cell-engager-programs\" title=\"Enara Bio strengthens senior leadership with key Executive and Board appointments alongside acceleration of multiple T-Cell engager programs\" class=\"state-published\">Enara Bio strengthens senior leadership with key Executive and Board appointments alongside acceleration of multiple T-Cell engager programs</a>\n            </h4>\n            \n            \n                \n\n    \n    \n        <ul class=\"list-unstyled list-inline categories-list\">\n\t        \n\t        \t\t<li>\n\t\t            <a href=\"https://www.bioescalator.ox.ac.uk/search?category=alumni-news\" title=\"Alumni news\">\n\t\t                <span class=\"label label-primary\">Alumni news</span>\n\t\t            </a>\n\t\t        </li>\n\t        \n\t   \t</ul>\n\n    \n\n\n            \n\n            \n                <p class=\"details\" itemprop=\"datePublished\">30 April 2025</p>\n            \n                            \n            \n                <p data-truncate=\"yes\" data-truncate-lines=\"2\">Enara Bio, a biopharmaceutical company pioneering the development of bispecific T-cell engagers directed against Dark Antigen\u00ae and other emerging targets, today announces the appointment of Stacey Davis as Chief Business Officer (CBO) and Chief Financial Officer (CFO). Her appointment strengthens the leadership team at a key moment for Enara as it prepares to transition its lead assets towards clinical development. Stacey most recently served as CBO at Xilio Therapeutics, where she was the architect of a series of major pharma collaborations. In total, Stacey brings over 25 years of experience in delivering growth, innovation, and strategic transformation in the biotech and pharmaceutical industries.</p>\n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/pepgen-announces-appointment-of-two-new-directors-to-its-board\" title=\"PepGen announces appointment of two new directors to its Board\" class=\"state-published\">PepGen announces appointment of two new directors to its Board</a>\n            </h4>\n            \n            \n                \n\n    \n    \n        <ul class=\"list-unstyled list-inline categories-list\">\n\t        \n\t        \t\t<li>\n\t\t            <a href=\"https://www.bioescalator.ox.ac.uk/search?category=alumni-news\" title=\"Alumni news\">\n\t\t                <span class=\"label label-primary\">Alumni news</span>\n\t\t            </a>\n\t\t        </li>\n\t        \n\t   \t</ul>\n\n    \n\n\n            \n\n            \n                <p class=\"details\" itemprop=\"datePublished\">30 March 2025</p>\n            \n                            \n            \n                <p data-truncate=\"yes\" data-truncate-lines=\"2\">PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the appointments of Lisa Wyman and Mitchell H. Finer, PhD, to its Board of Directors. Ms. Wyman and Dr. Finer are industry veterans, each bringing decades of executive experience in the life sciences to the Company.</p>\n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/moa-named-one-of-times-top-greentech-companies-in-2025\" title=\"Moa named one of TIME's top greentech companies in 2025\" class=\"state-published\">Moa named one of TIME's top greentech companies in 2025</a>\n            </h4>\n            \n            \n                \n\n    \n    \n        <ul class=\"list-unstyled list-inline categories-list\">\n\t        \n\t        \t\t<li>\n\t\t            <a href=\"https://www.bioescalator.ox.ac.uk/search?category=alumni-news\" title=\"Alumni news\">\n\t\t                <span class=\"label label-primary\">Alumni news</span>\n\t\t            </a>\n\t\t        </li>\n\t        \n\t   \t</ul>\n\n    \n\n\n            \n\n            \n                <p class=\"details\" itemprop=\"datePublished\">26 March 2025</p>\n            \n                            \n            \n                <p data-truncate=\"yes\" data-truncate-lines=\"2\">Moa recognised as leading global innovator in environmental impact.</p>\n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/moa-technology-forms-new-biological-partnership-with-naicons\" title=\"Moa forms new biological partnership with NAICONS\" class=\"state-published\">Moa forms new biological partnership with NAICONS</a>\n            </h4>\n            \n            \n                \n\n    \n    \n        <ul class=\"list-unstyled list-inline categories-list\">\n\t        \n\t        \t\t<li>\n\t\t            <a href=\"https://www.bioescalator.ox.ac.uk/search?category=alumni-news\" title=\"Alumni news\">\n\t\t                <span class=\"label label-primary\">Alumni news</span>\n\t\t            </a>\n\t\t        </li>\n\t        \n\t   \t</ul>\n\n    \n\n\n            \n\n            \n                <p class=\"details\" itemprop=\"datePublished\">25 March 2025</p>\n            \n                            \n            \n                <p data-truncate=\"yes\" data-truncate-lines=\"2\">Moa and NAICONS join forces to discover the next generation of naturally-occurring herbicides.</p>\n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/omass-therapeutics-appoints-birgitte-volck-as-non-executive-director\" title=\"OMass Therapeutics appoints Birgitte Volck as Non-Executive Director\" class=\"state-published\">OMass Therapeutics appoints Birgitte Volck as Non-Executive Director</a>\n            </h4>\n            \n            \n                \n\n    \n    \n        <ul class=\"list-unstyled list-inline categories-list\">\n\t        \n\t        \t\t<li>\n\t\t            <a href=\"https://www.bioescalator.ox.ac.uk/search?category=alumni-news\" title=\"Alumni news\">\n\t\t                <span class=\"label label-primary\">Alumni news</span>\n\t\t            </a>\n\t\t        </li>\n\t        \n\t   \t</ul>\n\n    \n\n\n            \n\n            \n                <p class=\"details\" itemprop=\"datePublished\">26 February 2025</p>\n            \n                            \n            \n                <p data-truncate=\"yes\" data-truncate-lines=\"2\">OMass Therapeutics (\u2018OMass\u2019 or \u2018the Company\u2019), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces that Birgitte Volck MD, PhD has joined its Board as a non-executive director.</p>\n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/enara-bio-embarks-on-a-research-collaboration-with-george-washington-university-to-deepen-understanding-of-dark-antigen-r-biology-and-expression\" title=\"Enara Bio embarks on a research collaboration with George Washington University to deepen understanding of Dark Antigen\u00ae biology and expression\" class=\"state-published\">Enara Bio embarks on a research collaboration with George Washington University to deepen understanding of Dark Antigen\u00ae biology and expression</a>\n            </h4>\n            \n            \n                \n\n    \n    \n        <ul class=\"list-unstyled list-inline categories-list\">\n\t        \n\t        \t\t<li>\n\t\t            <a href=\"https://www.bioescalator.ox.ac.uk/search?category=alumni-news\" title=\"Alumni news\">\n\t\t                <span class=\"label label-primary\">Alumni news</span>\n\t\t            </a>\n\t\t        </li>\n\t        \n\t   \t</ul>\n\n    \n\n\n            \n\n            \n                <p class=\"details\" itemprop=\"datePublished\">18 February 2025</p>\n            \n                            \n            \n                <p data-truncate=\"yes\" data-truncate-lines=\"2\">Collaboration may inform future combination strategies that can maximise the efficacy of Enara Bio\u2019s pipeline of TCR-based immunotherapies targeting Dark Antigens\u00ae</p>\n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n"
    ], 
    "more": "\n\n    \n        <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/moa-announces-international-field-trial-success-at-the-acs-autumn-conference-in-denver/search?category=alumni-news&amp;b_start:int=40&amp;format=json&amp;random=db527023-f280-42dc-bf0b-515f75da6dd3&amp;categories=alumni-news\" title=\"Load more\" class=\"btn btn-default load-more-button\">\n            Load More\n        </a>\n    \n\n", 
    "msg": ""
}